1. Home
  2. > Pharmaceutical
  3. > Therapy Market Trends
Middle East & Africa Glycomic Therapeutics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Class, Structures, Indications, Mode of Action

Middle East & Africa Glycomic Therapeutics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Class, Structures, Indications, Mode of Action

  • November 2022
  • 197 pages
  • ID: 6368941
  • Format: PDF
  • The Insight Partners

Summary

Table of Contents

Search Inside

The glycomic therapeutics market in the Middle East & Africa is expected to grow from US$ 5,785.63 million in 2022 to US$ 12,853.18 million by 2028; it is estimated to grow at a CAGR of 13.1% from 2022 to 2028.

New Tools in Glycomics Research to Drive Market Growth

Glycomics has the potential to pave the way for innovative treatment approaches by enhancing the characterization of molecules crucial for the development of diseases.It can be a substantial addition to technologies used in genomes and proteomics.

Comparative glycomics will be essential for identifying the glycans that cause the disease.There is a rising number of studies that will provide vital information on the relationship between clinical outcomes and glycomic anomalies.

Immunohistochemistry (IHC), Liquid Chromatography-Mass Spectrometry (LC-MS), and high-throughput fluorescence flow cytometry have been used to distinguish cell populations using glycoproteins.These are among the important technologies utilized to advance glycomics.

LC-MS can provide structural details about glycoconjugates by separating several glycoprotein isoforms from a single protein species. Unbiased surveys of cellular proteomes are now available due to high-throughput MS-based proteomics, and the method is swiftly applied to glycomics.

Structural reference databases are quickly emerging to close the gap between the variety and complexity of glycan structures.Identification of disease-related glycoconjugates by LC-MC, which employs antibody-based capture to view glycoconjugate expression with cell-staining or fluorescence, can be used to assess or validate IHC.

Targeting complete cells rather than tissue fragments, immunocytochemistry (ICC) reveals glycoprotein expression patterns at the cellular level utilizing the same imaging techniques as IHC.It will be possible to witness new aspects of glycomics, such as thorough characterization of metabolic junctions and pathways, by modifying IHC and ICC to concentrate on additional glycoconjugates, including glycolipids.

Tandem or multi-technology procedures, such as MS-IHC, would provide the analytical ability to labs to handle the glycoconjugates complexity and improve glycoconjugate diagnosis.The clinical applications of glycomics are catching up to those of genomics and proteomics due to the development of new high-throughput methods to study the structure and expression of glycans and ongoing innovation in glycan biomarkers and therapies.

Integrating glycomics will revolutionize precision medicine into an extensive omics strategy, providing new information on the interactions between genes, proteins, and glycans. The combination of omics data with digital health platforms has the potential to improve clinical trials and provides knowledge to researchers and doctors regarding illness. Owing to the rising scientific discoveries, widespread acceptance of glycomics and personalized medicine will necessitate significant changes in regulatory and reimbursement procedures and legislative privacy laws. Thus, customized healthcare challenges will be met and overcome with the assurance that the research behind glycomic therapeutics is adequate and that the practice of medicine is evidence-based.

Growing evidence of glycomics role in human health highlights the need to integrate glycomics into precision medicine.Cell surface expression of glycoconjugates determines in vivo recognition and in vitro interactions.

Microorganisms that perform important functions for their hosts, such as food digestion and vitamin synthesis and absorption, utilize complex carbohydrates to tell immune cells that they are not harmful. Pathogens that cause deadly diseases, such as tuberculosis and malaria, use similar strategies to evade attacks by the immune system.

Market Overview

The UAE, Saudi Arabia, and South Africa are the three major countries in the Middle East & South Africa.Saudi Arabia was the largest market for glycomic therapeutics in this region in 2022.

The market for glycomic therapeutics in the Middle East & Africa is anticipated to grow at a CAGR of 14.2% during the forecast period; this growth is attributed to the rising prevalence of cancer and metabolic diseases and increasing government initiatives in terms of funding and healthcare-related policies.

Middle East & Africa Glycomic Therapeutics Market Revenue and Forecast to 2028 (US$ Billion)

Middle East & Africa Glycomic Therapeutics Market Segmentation

The Middle East & Africa glycomic therapeutics market is segmented on the basis of class, structure, indications, mode of action, and country.

Based on class, the Middle East & Africa glycomic therapeutics market is bifurcated into isolated and synthetic.The synthetic segment registered a larger market share in 2022.

Based on structure, the Middle East & Africa glycomic therapeutics market is segmented into glycoproteins, targeting sialic acid, proteoglycans, targeting glycosaminoglycans, glycosylphosphatidylinositol (GPI)-anchored proteins & heparin based glycans, targeting glycosphingolipids, and others.The glycoproteins segment held the largest market share in 2022.

Based on indications, the Middle East & Africa glycomic therapeutics market is segmented into thrombosis & chemoprophylaxis, anaemia, anti-adhesive & anti-inflammatory, cataracts, gaucher’s disease, MPS-1 & IV, cancer, alzheimer’s disease, influenza type A & B, and others.The influenza type a & b segment held the largest market share in 2022.

Based on mode of action, the Middle East & Africa glycomic therapeutics market is segmented into inhibits neuraminidase, inhibits heparanase and selectins and blocks interactions between growth factors and heparan sulfate, erythropoietin & enzyme replacement therapy (ERT), tissue plasminogen activator, inhibits glucosylceramide synthase, interleukin 1 and 2 and 3, beta & gamma interferons, and others. The erythropoietin & enzyme replacement therapy (ERT) segment held the largest market share in 2022. Based on country, the Middle East & Africa glycomic therapeutics market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the market in 2022. Protalix Biotherapeutics; BioMarin Pharmaceutical Inc.; Genzyme Corporation (Sanofi); Bayer AG; GlaxoSmithKline plc.; and F. Hoffmann-La Roche Ltd. are the leading companies operating in the glycomic therapeutics in the Middle East & Africa.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Asia-Pacific Glycomic Therapeutics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Class, Structures, Indications, Mode of Action

  • $ 3000
  • November 2022
  • 210 pages

The glycomic therapeutics market in Asia Pacific is expected to grow from US$ 12,950.82 million in 2022 to US$ 34,592.83 million by 2028; it is estimated to grow at a CAGR of 17.8% from 2022 to 2028. Wide ...

  • APAC
  • Therapy
  • Genomics
  • Industry analysis
  • Cancer Incidence
  • Health Expenditure

ref:plp2022

Reportlinker.com © Copyright 2023. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on